Bioventus

Anybody has a guess on when something will happen? new products, acquisitions, etc.. many years now with S&N, I am just worried it may be another year or so until we see something

 

Nice try.

 

Well at least we all have jobs that have the endless potential to pay very well. But in order to grow, we need new products or at least new indications on the ones we have.

Wish we could retain a part time Medical Director who is an MD. What happened to the last one we had?

 

Frank Young is the new MD - http://www.fda.gov/AboutFDA/WhatWeDo/History/Leaders/Commissioners/ucm093728.htm

 

We need more people in the Reimbursement Department.

 

Yes. Need more Internal Reimbursement.

Another problem I see, it seems as though Insurance policies are getting worse, not better. Does anyone here call on Insurance Companies to negotiate and discuss potential cost savings?

 

? Haven't heard any announcements.

 

Maybe listening in to a conference call once in a blue moon would do the trick for you.

 

Gel One vs Supartz?

 

The man is 81 years old!

 

but Affordable.

 

"Defend your Kingdom, Dragon Slayers".
Your own your own and may the Defence Gods be with you.


Best of Luck!

 

Euflexxa and Synvisc/Synvisc One are a bigger target. Docs who use those products don't care about efficacy and less is better for them so they can do a knee replacement.

 

Synvisc One will be targeted at first, no doubt. But as time goes on, they will sneak their way into the clinics via the OR relationship. Remember, Zimmer reps have already been talking about it to their loyal surgeons, they just haven't been able to "sell" (exhange dollars) it.

Biggest fear next year, is the Blues taking 5's off formulary.

Biggest question is, "are we getting new products to help compensate the sales force which is mostly commissioned?"

 

LOL

 

It remains to be seen if Gel One is "equivalent." 13 weeks data.

Any competitor with accounts using Zimmer hardware look out. Expect Synvisc and Euflexxa reimbursement to take hits which caused many docs to use in the first place. So many variables out there.

 

To Management: Seikegaku better provide some concessions moving forward.

 

If we receive another dog turd like Scolioscore so we can have management once again rebuke us that we aren't doing a good job selling then please shoot me.

 

"Concessions"? what are you talking about? What concessions would you want Seikegaku to make?

 

I think Management understands that Scoliscore did not really "fit" into our portfolio. We have never called on Pediatric Orthopaedic Specialists. And they found out that General Orthopadic surgeons refer kids w AIS to Pediatric Specialists.

The product could have worked if we had the time to pull it through by calling on Pediatrics, school nurses, etc.
It's a great product, just not enough noise level and pull through.

What we need are "buy and bill" products. Products that are not labor and time intensive like Exogen. Joint Fluid therapy has been a great ride and it's a crying shame we didn't get Durolane here in the USA. Somebody really messed up by not giving the FDA a placebo study.